AstraZeneca’s COVID-19 Vaccine PR Nightmare Won’t Faze Investors

Other Readouts Expected In 2021

 
• By Andrew McConaghie

Comment: While the travails around the COVID-19 vaccine continue, AstraZeneca has plenty in its pipeline to cheer investors.

Astrazeneca
Despite all the doubts surrounding its COVID-19 vaccine, AstraZeneca's business is very much on the up

More from Business

More from Scrip